Leveraging Bayesian Techniques in DOE Model Prediction and Simulation to Enhance Decision-Making in the Context of Large-Molecule Process Characterization in the Pharmaceutical Setting

## Yang Cao & Jyh-Ming Shoung

Non-Clinical Statistics Conference September 25<sup>th</sup>, 2024 Wiesbaden, Germany

Johnson&Johnson Innovative Medicine



Drouville, In the fish tank

tient, graphic designer and artist from Argentina who has survived multiple myeloma and a relapse

## process characterization



High resolution purification steps

**Criticality—which parameters critically impact the quality of product? Proven acceptable range (PAR)--what ranges of the parameters are acceptable?** 

**J&J** Innovative Medicine

Image source: https://www.sciencedirect.com/science/article/pii/S1517838216310413





### Final biophameceutical







# **Proposed statistical workflow for criticality and PAR assessment**



**J&J** Innovative Medicine

**CPP: Critical Process Parameter** PAR: Proven Acceptable Range

# Which parameters are critical?





# Which parameters are critical?



## J&J Innovative Medicine

\*Hakemeyer C, McKnight N, St John R, Meier S, Trexler-Schmidt M, Kelley X2, Zettl F, Puskeiler R, Kleinjans X1, Lim F, Wurth C. Process characterization and Design Space definition. Biologicals. 2016 Sep;44(5):306-18. doi: 10.1016/j.X2iologicals.2016.06.004. Epub 2016 Jul 25. PMID: 27464992.

### Assessment

## **Critical Parameters**



# Which parameters are critical?



**J&J** Innovative Medicine

\*Hakemeyer C, McKnight N, St John R, Meier S, Trexler-Schmidt M, Kelley X2, Zettl F, Puskeiler R, Kleinjans X1, Lim F, Wurth C. Process characterization and Design Space definition. Biologicals. 2016 Sep;44(5):306-18. doi: 10.1016/j.X2iologicals.2016.06.004. Epub 2016 Jul 25. PMID: 27464992.

### Assessment

# **Critical Parameters**

## Based on DOE

# We are proposing an effect-to-noise ratio, calculated based on DOE model

It allows for consistent and fair comparison, even when process knowledge is limited





# We are proposing an effect-to-noise ratio, calculated based on DOE model





## Parameter effect size (X<sub>2</sub>): main effects +interactions

DOE Model: CQA=94.7 -2\* X<sub>1</sub> +4.3\* X<sub>2</sub> -3\* X<sub>1</sub> X<sub>2</sub>



What is the parameter effect size for  $X_2$ ?

## **Parameter effect size: main effects +interactions**

Grid-Search Illustration\*--can be universally applied, accounting for applicable interactions and curvatures



Parameter effect size of  $X_2$  = the max length of the vertical arrows=14.65 It quantifies the magnitude change in CQA due to  $X_2$  when fixing other significant parameter at a level that results in the greatest impact

**J&J** Innovative Medicine

\*F. Li et al., "Removing Subjectivity from the Assessment of Critical Process Parameters and Their Impact," Pharmaceutical Technology 42 (1) 2018.

## **Effect-to-noise ratio**



The max magnitude change in CQA due to X<sub>2</sub> is 5.75 times the noise

Now, can we do better and account for model uncertainty?



## Yes ! Instead of estimates, we can get distributions, thanks to Bayesian





# Now, we have a distribution of effect-to-noise ratio from Bayesian



# What is the certainty that the effect is real rather than noise?



Pr*ob* (e*ffect*> noise) < 50%

**50%≤** Pr*ob*(e*ffect*> noise)< 80%

**J&J** Innovative Medicine





## $80\% \leq Prob$ (effect> noise)

## We can leverage the distribution of effect-to-noise ratio to assess certainty



## Estimate based on Frequentist=5.7

## Estimates based on Bayesian

Bound	//0 23/0 20/0 10/0
Ratio 1.0 3.2 3.9 4.2 5.3	3 6.6 6.9 7.8

99.8% certainty that the effect is greater than noise



## We can leverage the distribution of effect-to-noise ratio to assess criticality



## Estimate based on Frequentist=5.7

Estimates	based	on	Bayesian
-----------	-------	----	----------

Lower Bound	99.8%	90%	80%	75%	50%	25%	20%	10%
Ratio	1.0	3.2	3.9	4.2	5.3	6.6	6.9	7.8

90% chance that the effect is at least 3.2 times the noise

X<sub>2</sub> might be considered a CPP since there is a high chance that its impact is practically significant relative to the noise



# **Proposed statistical workflow for criticality and PAR assessment**



**J&J** Innovative Medicine

## **CPP:** Critical Process Parameter PAR: Proven Acceptable Range

# **Proven acceptable range (PAR) definition**

PAR defined in ICH Q8 (R2) : "a characterized range of a process parameter for which operation within this range, while keeping other parameters constant, will result in producing a material meeting relevant quality criteria".

# **Proven acceptable range (PAR) definition**

at all possible extreme conditions

PAR defined in ICH Q8 (R2) : "a characterized range of a process parameter for which operation within this range, while keeping other parameters constant, will result in producing a material meeting relevant quality criteria".

at target or normal operating range

# **Proven acceptable range (PAR) for X<sub>1</sub> in Monte Carlo simulation**

Run simulations at the extreme case conditions for  $X_1$ , while keeping  $X_2$  at target CQA=94.7 - 2\* X<sub>1</sub> + 4.3\* X<sub>2</sub> - 3\* X<sub>1</sub> X<sub>2</sub> 0 1 -1  $X_1$ -1 n **J&J** Innovative Medicine  $X_1$ 



# **Proven acceptable range (PAR) for X<sub>1</sub> in Monte Carlo simulation**

Run simulations at the extreme case conditions for  $X_1$ , while keeping  $X_2$  at target CQA=94.7 -  $2^* X_1 + 4.3^* X_2 - 3^* X_1 X_2$ 



We applied fixed coefficients, which didn't account for model uncertainty ~~~ Can we improve?



## Yes ! We can simulate Y using a distribution of model coefficients, thanks to Bayesian

Run simulations at the extreme case conditions for  $X_1$ , while keeping  $X_2$  at target CQA=94.7 -  $2^* X_1$  + 4.3  $X_2$  -  $3^* X_1 X_2$ 





## A single estimate of failure %(Frequentist) v.s. a distribution of failure % (Bayesian)



Failure Rate=% simulated CQA fall outside the specifications/Acceptable limits



-	

95%	99%
2.3	9.2

# **Bayesian approach additionally accounts for model uncertainty**



PAR of X<sub>1</sub> might need to be narrowed to ensure a failure rate <5% with 90% probability

# What we proposed





**Improve Bayesian distribution with** scientific knowledge (e.g., informative prior)

Bayesian enhanced statistical workflow to facilitate the decisionmaking in the context of process characterization





Run more proof-of-concept examples



## **Continue the discussion to finalize**

J&J Innovative Medicine

# sanofi

William Eberley

Yi Li

Canghai Lu

Yukun Ren

Jiayi Zhang

## Johnson&Johnson

**Bill Pikounis** 

Hong Shen